menu
    • menu
    [{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Cannabidiol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Innocan Pharma \/ Research Capital Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Innocan Pharma \/ Research Capital Corporation"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Cannabidiol","moa":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Innocan Pharma \/ Research Capital Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Innocan Pharma \/ Research Capital Corporation"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Podiatry","graph2":"Preclinical","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Cream","sponsorNew":"Innocan Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Innocan Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innocan Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Innocan Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innocan Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Innocan Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Hebrew University","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Cannabidiol","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innocan Pharma \/ Hebrew University","highestDevelopmentStatusID":"4","companyTruncated":"Innocan Pharma \/ Hebrew University"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innocan Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Innocan Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innocan Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Innocan Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Innocan Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Innocan Pharma \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Innocan Pharma

    Menu

    Innocan Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Innocan Pharma

                            Israel arrow
                            Fi Europe 2024
                            Not Confirmed

                            Innocan Pharma

                            Israel arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Innocan Pharma Announces Successful Preliminary Safety Evaluation of LPT-CBD in Minipigs

                            Details : LPT CBD (cannabinoid) is a loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into blood stream. It is being evaluated for chronic pain management.

                            Brand Name : LPT-CBD

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 11, 2024

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Innocan Pharma

                            Israel arrow
                            Fi Europe 2024
                            Not Confirmed

                            Innocan Pharma

                            Israel arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Innocan Pharma Begins FDA Approval Process for Liposome Injection Therapy for Chronic Pain

                            Details : LPT CBD (cannabinoid) is a loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. It is being evaluated for chronic pain management.

                            Brand Name : LPT-CBD

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 22, 2024

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Innocan Pharma

                            Israel arrow
                            Fi Europe 2024
                            Not Confirmed

                            Innocan Pharma

                            Israel arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Hebrew University

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Innocan Pharma Advances LPT-CBD CMC for FDA Approval

                            Details : The agreement helps Innocan initiate FDA approval for its liposome CBD platform (LPT-CBD), which enables controlled release of CBD in the bloodstream for treating epilepsy and pain management.

                            Brand Name : LPT-CBD

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 25, 2024

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Hebrew University

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Innocan Pharma

                            Israel arrow
                            Fi Europe 2024
                            Not Confirmed

                            Innocan Pharma

                            Israel arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Innocan LPT-CBD Shows Potential for Neurological Disorders, According to New Study

                            Details : LPT-CBD (cannabidiol) is a CB1 receptor negative allosteric modulator, which is being evaluated for the treatment of patients suffering from neurological diseases.

                            Brand Name : LPT-CBD

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 05, 2024

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Innocan Pharma

                            Israel arrow
                            Fi Europe 2024
                            Not Confirmed

                            Innocan Pharma

                            Israel arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Innocan Finds LPT-CBD Maintains Prolonged Release in Rabbit Studies

                            Details : LPT CBD is a loaded liposome platform for precise dosing and controlled CBD release, being evaluated for epilepsy treatment and pain management.

                            Brand Name : LPT-CBD

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 26, 2024

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Innocan Pharma

                            Israel arrow
                            Fi Europe 2024
                            Not Confirmed

                            Innocan Pharma

                            Israel arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Innocan Pharma Reports a Groundbreaking Discovery Regarding Its LPD Platform and Global CBD Research

                            Details : Cannabidiol is a CB1 receptor negative allosteric modulator (NAM), which is being evaluated in preclinical studies for the treatment of Pain.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 23, 2023

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Innocan Pharma

                            Israel arrow
                            Fi Europe 2024
                            Not Confirmed

                            Innocan Pharma

                            Israel arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Sponsor : Research Capital Corporation

                            Deal Size : $1.6 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Innocan Pharma Announces Closing of Second and Final Tranche of Financing

                            Details : The Company intends to use the net proceeds to fund the Company's pre-investigational new drug meeting regarding the human application of the Company's products, including Cannabidiol.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 20, 2023

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Sponsor : Research Capital Corporation

                            Deal Size : $1.6 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Innocan Pharma

                            Israel arrow
                            Fi Europe 2024
                            Not Confirmed

                            Innocan Pharma

                            Israel arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol,Menthol,Camphor

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Research Capital Corporation

                            Deal Size : Undisclosed

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Innocan Pharma Announces Closing of First Tranche Private Placement and Provides Corporate Update

                            Details : The Company intends to use the net proceeds from the Offering to fund the Company's pre-investigational new drug meeting with the United States FDA regarding the human application and expansion of the Company's derma-cosmetic product distribution.

                            Brand Name : Relief & Go

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 12, 2023

                            Lead Product(s) : Cannabidiol,Menthol,Camphor

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Research Capital Corporation

                            Deal Size : Undisclosed

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Innocan Pharma

                            Israel arrow
                            Fi Europe 2024
                            Not Confirmed

                            Innocan Pharma

                            Israel arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Podiatry

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Innocan Pharma Announces Promising Successful Results in Efficacy Trial of Diabetic Foot Relief Treatment

                            Details : Cannabidiol is a topical CB1 receptor negative allosteric modulator (NAM), which is being evaluated in phase 1 clinical studies for the treatment of Diabetic Foot.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 15, 2023

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Podiatry

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth